Sanctuary Advisors LLC Makes New $540,000 Investment in Xencor, Inc. (NASDAQ:XNCR)

Sanctuary Advisors LLC bought a new position in Xencor, Inc. (NASDAQ:XNCR) in the 3rd quarter, Holdings Channel.com reports. The fund bought 26,831 shares of the biopharmaceutical company’s stock, valued at approximately $540,000.

A number of other institutional investors have also modified their holdings of XNCR. Panagora Asset Management Inc. increased its holdings in Xencor by 9.4% in the second quarter. Panagora Asset Management Inc. now owns 232,375 shares of the biopharmaceutical company’s stock valued at $4,399,000 after buying an additional 20,043 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Xencor by 0.3% in the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after acquiring an additional 25,495 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Xencor during the 2nd quarter valued at approximately $753,000. Barclays PLC lifted its stake in Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Xencor by 6.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after purchasing an additional 87,979 shares during the period.

Xencor Stock Down 1.1 %

Shares of Xencor stock opened at $24.29 on Thursday. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $27.24. The company has a market capitalization of $1.70 billion, a P/E ratio of -7.59 and a beta of 0.69. The business’s fifty day moving average price is $23.59 and its two-hundred day moving average price is $20.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. The company’s quarterly revenue was down 81.9% compared to the same quarter last year. As a group, research analysts forecast that Xencor, Inc. will post -3.71 EPS for the current year.

Insider Activity

In related news, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the sale, the vice president now owns 200,104 shares of the company’s stock, valued at $4,698,441.92. The trade was a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan Bruce Montgomery sold 13,301 shares of Xencor stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $27.03, for a total value of $359,526.03. Following the transaction, the director now owns 9,140 shares in the company, valued at approximately $247,054.20. This trade represents a 59.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 136,050 shares of company stock worth $3,277,609 over the last three months. Corporate insiders own 5.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and set a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company started coverage on Xencor in a research note on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price for the company. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Finally, Royal Bank of Canada boosted their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $36.56.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.